Deuterated catecholamine derivatives and medicaments comprising said compounds
The present invention concerns deuterated catecholamine derivatives as well as pharmaceuticals containing these compounds. In addition, the invention concerns the use of deuterated catecholamine derivatives as well as physiologically compatible salts thereof, and also pharmaceutical compositions, which contain these compounds, also in combination with enzyme inhibitors, for the treatment of dopamine deficiency diseases or diseases which are based on disrupted tyrosine transport or disrupted tyrosine decarboxylase, as well as other disorders.
1. Deuterated catecholamine derivatives of the general formula I
wherein R 1 is H or D, R2 indicates D, R 3 is H, D, C 1 to C 6 -alkyl or C 5 to C 6 -cycloalkyl, deuterated C 1 to C 6 -alkyl or deuterated C 5 to C 6 -cycloalkyl, R 4 indicates H or D and R 5 is H or hhD.
2. Deuterated catecholamine derivatives of the general formula I
wherein R 1 is H or D, R 2 indicates D, R 3 is D, C 1 to C 6 -alkyl or C 5 to C 6 -cycloalkyl, deuterated C 1 to C 6 -alkyl or deuterated C 5 to C 6 -cycloalkyl, R 4 indicates H or D and R 5 is H or D.
3. Deuterated catecholamine derivatives of the general formula I
wherein R 1 is H or D, R 2 indicates D, R 3 is H, D, C 1 to C 6 -alkyl or C 5 to C 6 -cycloalkyl, deuterated C 1 to C 6 -alkyl or deuterated C 5 to C 6 -cycloalkyl, R 4 indicates H or D and R 5 is H or D.
4. Deuterated catecholamine derivatives of the general formula I
wherein R 1 is H or D, R 2 indicates D, R 3 is C 1 to C 6 -alkyl or C 5 to C 6 -cycloalkyl, R 4 indicates H or D and R 5 is H or D.
5. Deuterated catecholamine derivatives of the general formula I
wherein R 1 is H or D, R 2 indicates D, R 3 is methyl, R 4 indicates H or D and R 5 is H or D.
6. Deuterated catecholamine derivatives of the general formula I
wherein R 1 is H or D, R 2 indicates D, R 3 is ethyl, R 4 indicates H or D and R 5 is H or D.
7. Deuterated catecholamine derivatives of the general formula I
wherein R 1 is H or D, R 2 indicates D, R 3 is perdeuteroethyl, R 4 indicates H or D and R 5 is H or D.
8. Deuterated catecholamine derivatives of the general formula I
wherein R 1 is H or D, R2 indicates D, R 3 is perdeuteroethyl, R 4 indicates H or D and R 5 is H or D.
9. Deuterated catecholamine derivatives of the general formula I
wherein R 1 is H or D, R 2 indicates D, R 3 is perdeuteroethyl, R 4 indicates D and R 5 is H or D.
10. A method for the treatment of dopamine deficiency diseases or diseases which are based on disrupted tyrosine transport or disrupted tyrosine decarboxylase, or Parkinson's disease, restless leg syndrome, dystonia, for inhibiting prolactin secretion, for stimulating the release of growth hormone, for the treatment of neurological symptoms of chronic manganese intoxications, of amyotrophic lateral sclerosis and of multiple system atrophy, said method comprising administering to a patient in need thereof an effective amount of a compound of general formula I
wherein R 1 is H or D, R 2 indicates D, R 3 is H, D, C 1 -C 6 alkyl or C 5 to C 6 -cycloalkyl, deuterated C 1 to C 6 -alkyl or C 5 to C 6 -cycloalkyl, R 4 indicates H or D and R 5 is H or D, and wherein the compound is selected from the group consisting of
L-2-amino-2,3,3-trideutero-3-(3,4-dihydroxyphenyl)propionic acid;
L-2-amino-2,3,3-trideutero-3-(3,4-dihydroxyphenyl)methyl propionate;
L-2-amino-2,3,3-trideutero-3-(3,4-dihydroxyphenyl)ethyl propionate;
L-2-amino-2,3,3-trideutero-3-(3,4-dihydroxyphenyl)cyclohexyl propionate;
L-2-amino-2,3,3-trideutero-3-(3,4-dihydroxyphenyl)perdeuteromethyl propionate;
L-2-amino-2,3,3-trideutero-3-(3,4-dihydroxyphenyl)perdeuteroethyl propionate;
L-2-amino-2,3,3-trideutero-3-(3,4-dihydroxyphenyl)perdeuterocyclohexyl propionate;
L-2-amino-2,3,3-trideutero-3-(2,3,6-trideutero-4,5-dihydroxyphenyl)propionic acid;
L-2-amino-2,3,3-trideutero-3-(2,3,6-trideutero-4,5-dihydroxyphenyl)methyl propionate;
L-2-amino-2,3,3-trideutero-3-(2,3,6-trideutero-4,5-dihydroxyphenyl)ethyl propionate;
L-2-amino-2,3,3-trideutero-3-(2,3,6-trideutero-4,5-dihydroxyphenyl)cyclohexyl propionate;
L-2-amino-2,3,3-trideutero-3-(2,3,6-trideutero-4,5-dihydroxyphenyl)perdeuteromethyl propionate;
L-2-amino-2,3,3-trideutero-3-(2,3,6-trideutero-4,5-dihydroxyphenyl)perdeuteroethyl propionate;
L-2-amino-2,3,3-trideutero-3-(2,3,6-trideutero-4,5-dihydroxyphenyl)perdeuterocyclohexyl propionate;
L-2-amino-2,3,3-trideutero-3-(2,3,6-trideutero-4,5-dideuteroxyphenyl)perdeuterocyclohexyl propionate; and,
as well as physiologically compatible salts thereof.
11. The method of claim 10 , wherein the compound as well as physiologically compatible salts thereof is administered in combination with an enzyme inhibitor or several enzyme inhibitors.
12. The method as claimed in claim 11 wherein the enzyme inhibitor or the enzyme inhibitors involve decarboxylase inhibitors and/or catechol-O-methyltransferase inhibitors and/or monoamine oxidase inhibitors and/or β-hydroxylase inhibitors.
13. The method as claimed in claim 12 wherein the decarboxylase inhibitor is selected from the group consisting of D,L-serine 2-(2,3,4-trihydroxybenzyl) hydrazide (benserazide), (−)-L-α-hydrazino-3,4-dihydroxy-α-methylhydrocinnamic acid (carbidopa), L-serine 2-(2,3,4-trihydroxybenzyl)hydrazide, glycine 2-(2,3,4-trihydroxybenzyl) hydrazide and L-tyrosine 2-(2,3,4-trihydroxybenzyl)hydrazide as well as physiologically compatible salts thereof.
14. The method as claimed in claim 12 wherein the catechol-O-methyltransferase inhibitor is selected from entacapone and cabergoline as well as physiologically compatible salts thereof.
15. The method as claimed in claim 12 wherein the monoamine oxidase inhibitor is selected from the group consisting of selegiline, moclobemide and tranylcypromine as well as physiologically compatible salts thereof.
16. The method as claimed in claim 12 wherein the β-hydroxylase inhibitor is selected from calcium 5-butyl picolinate and calcium 5-pentyl picolinate as well as physiologically compatible salts thereof.
17. A method for the production of pharmaceuticals for treatment of dopamine deficiency diseases or diseases which are based on disrupted tyrosine transport or disrupted tyrosine decarboxylase, or Parkinson's disease, restless leg syndrome, dystonia, for inhibiting prolactin secretion, for stimulating the release of growth hormone, for the treatment of neurological symptoms of chronic manganese intoxications, of amyotrophic lateral sclerosis and of multiple system atrophy, said method comprising the steps of providing a compound of general formula I
wherein R 1 is H or D, R 2 indicates D, R 3 is H, D, C 1 -C 6 alkyl or C 5 to C 6 -cycloalkyl, deuterated C 1 to C 6 -alkyl or C 5 to C 6 -cycloalkyl, R 4 indicates H or D and R 5 is H or D, and wherein the compound is selected from the group consisting of
L-2-amino-2,3,3-trideutero-3-(3,4-dihydroxyphenyl)propionic acid;
L-2-amino-2,3,3-trideutero-3-(3,4-dihydroxyphenyl)methyl propionate;
L-2-amino-2,3,3-trideutero-3-(3,4-dihydroxyphenyl)ethyl propionate;
L-2-amino-2,3,3-trideutero-3-(3,4-dihydroxyphenyl)cyclohexyl propionate;
L-2-amino-2,3,3-trideutero-3-(3,4-dihydroxyphenyl)perdeuteromethyl propionate;
L-2-amino-2,3,3-trideutero-3-(3,4-dihydroxyphenyl)perdeuteroethyl propionate;
L-2-amino-2,3,3-trideutero-3-(3,4-dihydroxyphenyl)perdeuterocyclohexyl propionate;
L-2-amino-2,3,3-trideutero-3-(2,3,6-trideutero-4,5-dihydroxyphenyl)propionic acid;
L-2-amino-2,3,3-trideutero-3-(2,3,6-trideutero-4,5-dihydroxyphenyl)methyl propionate;
L-2-amino-2,3,3-trideutero-3-(2,3,6-trideutero-4,5-dihydroxyphenyl)ethyl propionate;
L-2-amino-2,3,3-trideutero-3-(2,3,6-trideutero-4,5-dihydroxyphenyl)cyclohexyl propionate;
L-2-amino-2,3,3-trideutero-3-(2,3,6-trideutero-4,5-dihydroxyphenyl)perdeuteromethyl propionate;
L-2-amino-2,3,3-trideutero-3-(2,3,6-trideutero-4,5-dihydroxyphenyl)perdeuteroethyl propionate;
L-2-amino-2,3,3-trideutero-3-(2,3,6-trideutero-4,5-dihydroxyphenyl)perdeuterocyclohexyl propionate;
L-2-amino-2,3,3-trideutero-3-(2,3,6-trideutero-4,5-dideuteroxyphenyl)perdeuterocyclohexyl propionate; and
as well as physiologically compatible salts thereof and combining said compound and physiologically compatible salts with pharmaceutically compatible adjuvants and additives.
18. A pharmaceutical composition for the treatment of Parkinson's disease, of restless leg syndrome, of dystonia, for inhibiting prolactin secretion, for stimulating the release of growth hormone, for the treatment of neurological symptoms of chronic manganese intoxications, of amyotrophic lateral sclerosis and of multiple system atrophy, which pharmaceutical composition comprises a compound of general formula I
wherein R 1 is H or D, R 2 indicates D, R 3 is H, D, C 1 -C 6 alkyl or C 5 to C 6 -cycloalkyl, deuterated C 1 to C 6 -alkyl or C 5 to C 6 -cycloalkyl, R 4 indicates H or D and R 5 is H or D, and wherein the compound is selected from the group consisting of
L-2-amino-2,3,3-trideutero-3-(3,4-dihydroxyphenyl)propionic acid;
L-2-amino-2,3,3-trideutero-3-(3,4-dihydroxyphenyl)methyl propionate;
L-2-amino-2,3,3-trideutero-3-(3,4-dihydroxyphenyl)ethyl propionate;
L-2-amino-2,3,3-trideutero-3-(3,4-dihydroxyphenyl)cyclohexyl propionate;
L-2-amino-2,3,3-trideutero-3-(3,4-dihydroxyphenyl)perdeuteromethyl propionate;
L-2-amino-2,3,3-trideutero-3-(3,4-dihydroxyphenyl)perdeuteroethyl propionate;
L-2-amino-2,3,3-trideutero-3-(3,4-dihydroxyphenyl)perdeuterocyclohexyl propionate;
L-2-amino-2,3,3-trideutero-3-(2,3,6-trideutero-4,5-dihydroxyphenyl)propionic acid;
L-2-amino-2,3,3-trideutero-3-(2,3,6-trideutero-4,5-dihydroxyphenyl)methyl propionate;
L-2-amino-2,3,3-trideutero-3-(2,3,6-trideutero-4,5-dihydroxyphenyl)ethyl propionate;
L-2-amino-2,3,3-trideutero-3-(2,3,6-trideutero-4,5-dihydroxyphenyl)cyclohexyl propionate;
L-2-amino-2,3,3-trideutero-3-(2,3,6-trideutero-4,5-dihydroxyphenyl)perdeuteromethyl propionate;
L-2-amino-2,3,3-trideutero-3-(2,3,6-trideutero-4,5-dihydroxyphenyl)perdeuteroethyl propionate;
L-2-amino-2,3,3-trideutero-3-(2,3,6-trideutero-4,5-dihydroxyphenyl)perdeuterocyclohexyl propionate;
L-2-amino-2,3,3-trideutero-3-(2,3,6-trideutero-4,5-dideuteroxyphenyl)perdeuterocyclohexyl propionate; and
as well as physiologically compatible salts thereof, in addition to pharmaceutically compatible adjuvants and additives.
19. The pharmaceutical composition of claim 18 further comprising one or more enzyme inhibitors.
20. The pharmaceutical composition according to claim 19 , further characterized in that the enzyme inhibitor or the enzyme inhibitors involve decarboxylase inhibitors and/or catechol-O-methyltransferase inhibitors and/or monoamine oxidase inhibitors and/or β-hydroxylase inhibitors.
21. The pharmaceutical composition according to claim 19 , further characterized in that the decarboxylase inhibitor is selected from the group consisting of D,L-serine 2-(2,3,4-trihydroxybenzyl)hydrazide(benserazide), (−)-L-α-hydrazino-3,4-dihydroxy-α-methylhydrocinnamic acid(carbidopa), L-serine 2-(2,3,4-trihydroxybenzyl)hydrazide, glycine 2-(2,3,4-trihydroxybenzyl)hydrazide and L-tyrosine 2-(2,3,4-trihydroxybenzyl)hydrazide as well as physiologically compatible salts thereof.
22. The pharmaceutical composition according to claim 19 , further characterized in that the catechol-O-methyltransferase inhibitor is selected from entacapone and cabergoline as well as physiologically compatible salts thereof.
23. The pharmaceutical composition according to claim 19 , further characterized in that the monoamine oxidase inhibitor is selected from the group consisting of selegiline, moclobemide and tranylcypromine as well as physiologically compatible salts thereof.
24. The pharmaceutical composition according to claim 19 , further characterized in that the β-hydroxylase inhibitor is selected from calcium 5-butyl picolinate and calcium 5-pentyl picolinate as well as physiologically compatible salts thereof.